Neuro-SysMed Seminar August 19, 2026
Welcome to the Neuro-SysMed monthly seminar series! Join us at the auditorium in Olavssalen from 11:30 to 13:00 (lunch will be served from 11:30 to 12:00). This time, we will hear from Christian Dölle and Monica Jordheim, who will will introduce the planned research activities of work package 1 (WP1) of the newly established Center for Research-driven Innovation, Center for Neuroresilience (SFI ICoN).
Speakers
Researcher Christian Dölle, Neuro-SysMed and ICoN, and Professor Monica Jordheim.
Christian Dölle is a senior researcher affiliated with Neuro-SysMed’s PD group and will be heading WP1 of ICoN together with Monica Jordheim. Dölle is an expert in cell and molecular biology with experience in advanced in vitro and cell models for testing of interventions affecting neuroinflammation and neurodegeneration.
Monica Jordheim is a Professor at the Department of Chemistry at UiB and Vice Dean for Education at the Faculty of Science and Technology, UiB. Jordheim's main research interests are to enhance scientific knowledge and application value of natural products. Jordheim has over twenty years of experience in the isolation, identification and purity assessment of natural products, including bioactive fractions and pure compounds, and she will contribute to ICoN WP1 with her expertise in drug development and by providing natural compounds for prevention of neurodegeneration to be tested in preclinical model systems.
Topic
"Finding novel treatment candidates to enhance neuroresilience in α-synucleinopathies."
Registration
Registration through this link (external link). The deadline if you would like to join the lunch is Aug. 17 at 11.00. Till the seminar starts, if not.
Time and place
Place: Olavssalen, Gamle hovudbygg, Haukeland universitetssjukehus
When: August 19, 2026 at 11:30 - 13:00 (lunch 11:30 - 12:00).
Abstract
In the newly established Innovation Center for Neuroresilience (ICoN), one work package aims to identify, prioritise, and nominate candidate disease-modifying treatments (DMTs) for clinical testing in α-synucleinopathies. This comprises existing compounds from pharmaceutical and supplement industry but focuses also on the discovery and characterization of novel compounds with neuroprotective properties, sourced from marine biomass harvested on the Norwegian coast.
The seminar will provide an overview of the activities of this work package of ICoN, and will introduce aspects of harvesting, isolating, and analysing low-complexity mixtures and compounds, and discuss the development of methodologies and approaches in the field.
Moreover, screening approaches to assess neuroprotective properties such as inhibition of in vitro α-synuclein aggregation, anti-inflammatory effects, and protection against cell-organellar stress will be discussed.